Inge M. van Oort

12.9k total citations · 5 hit papers
193 papers, 7.0k citations indexed

About

Inge M. van Oort is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Inge M. van Oort has authored 193 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 56 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Inge M. van Oort's work include Prostate Cancer Treatment and Research (153 papers), Prostate Cancer Diagnosis and Treatment (79 papers) and Radiopharmaceutical Chemistry and Applications (41 papers). Inge M. van Oort is often cited by papers focused on Prostate Cancer Treatment and Research (153 papers), Prostate Cancer Diagnosis and Treatment (79 papers) and Radiopharmaceutical Chemistry and Applications (41 papers). Inge M. van Oort collaborates with scholars based in Netherlands, United States and Italy. Inge M. van Oort's co-authors include J. Alfred Witjes, Jelle O. Barentsz, Jack A. Schalken, Diederik M. Somford, Thomas Hambrock, Christina A. Hulsbergen‐van de Kaa, Henkjan Huisman, Jurgen J. Fütterer, Lambertus A. Kiemeney and Caroline Hoeks and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Inge M. van Oort

180 papers receiving 6.9k citations

Hit Papers

Prostate Cancer: Multiparametric MR Imaging for Detectio... 2003 2026 2010 2018 2011 2003 2018 2011 2021 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging
    2011 542 citations Jelle O. Barentsz, Thomas Hambrock et al. profile →
  2. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
    2003 532 citations Inge M. van Oort, Lambertus A. Kiemeney et al. profile →
  3. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study
    2018 520 citations Bas Israël, Patrik Zámecnik et al. profile →
  4. Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer
    2011 481 citations Thomas Hambrock, Diederik M. Somford et al. profile →
  5. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
    2021 183 citations Johann S. de Bono, Niven Mehra et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inge M. van Oort Netherlands 41 5.4k 2.1k 1.2k 1.2k 1.2k 193 7.0k
Thomas Steuber Germany 42 5.1k 0.9× 870 0.4× 1.3k 1.0× 1.4k 1.1× 1.3k 1.1× 210 6.5k
Samson W. Fine United States 48 5.1k 0.9× 1.3k 0.6× 940 0.8× 1.3k 1.1× 1.8k 1.5× 160 7.6k
Scott Williams Australia 41 4.7k 0.9× 2.3k 1.1× 658 0.5× 522 0.4× 575 0.5× 164 6.5k
Piet Ost Belgium 44 5.9k 1.1× 2.2k 1.0× 1.1k 0.9× 688 0.6× 659 0.6× 249 7.9k
Thomas Wiegel Germany 38 8.2k 1.5× 1.7k 0.8× 1.1k 0.9× 1.6k 1.3× 838 0.7× 232 10.5k
Daniel E. Spratt United States 44 4.8k 0.9× 1.4k 0.6× 1.1k 0.9× 512 0.4× 923 0.8× 408 8.2k
Michael A. Gorin United States 49 5.9k 1.1× 2.6k 1.2× 1.2k 1.0× 682 0.5× 2.3k 2.0× 327 9.3k
Hans Heinzer Germany 34 3.5k 0.6× 698 0.3× 634 0.5× 910 0.7× 752 0.6× 185 4.7k
Soroush Rais‐Bahrami United States 43 5.5k 1.0× 1.8k 0.8× 346 0.3× 1.9k 1.5× 1.1k 0.9× 288 7.5k
Raymond Miralbell Switzerland 49 4.5k 0.8× 2.1k 1.0× 565 0.5× 510 0.4× 490 0.4× 216 7.7k

Countries citing papers authored by Inge M. van Oort

Since Specialization
Citations

This map shows the geographic impact of Inge M. van Oort's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge M. van Oort with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge M. van Oort more than expected).

Fields of papers citing papers by Inge M. van Oort

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge M. van Oort. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge M. van Oort. The network helps show where Inge M. van Oort may publish in the future.

Co-authorship network of co-authors of Inge M. van Oort

This figure shows the co-authorship network connecting the top 25 collaborators of Inge M. van Oort. A scholar is included among the top collaborators of Inge M. van Oort based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge M. van Oort. Inge M. van Oort is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Privé, Bastiaan M., Tim M. Govers, Bas Israël, et al.. (2025). A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3159–3169. 1 indexed citations
3.
Oort, Inge M. van, et al.. (2024). Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?. European Radiology. 34(12). 7698–7704. 5 indexed citations
4.
Ausems, Margreet G.E.M., Lambertus A. Kiemeney, Harm H.E. van Melick, et al.. (2024). Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 28(3). 789–794. 1 indexed citations
5.
Privé, Bastiaan M., Maarten J. van der Doelen, James Nagarajah, et al.. (2024). Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 14(12). 4555–4569. 6 indexed citations
6.
Tolmeijer, Sofie H., Takayuki Sumiyoshi, Edmond M. Kwan, et al.. (2023). Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(15). 2835–2844. 26 indexed citations
7.
Castro, Elena, Douglas Laird, Shuang G. Zhao, et al.. (2023). 1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1. Annals of Oncology. 34. S983–S984. 2 indexed citations
8.
Oort, Inge M. van, et al.. (2023). Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. Cancers. 15(10). 2814–2814. 8 indexed citations
9.
Mehra, Niven, et al.. (2023). Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide. Clinical Pharmacokinetics. 62(8). 1049–1061. 8 indexed citations
10.
Somford, Diederik M., Paul Hamberg, Jolien Tol, et al.. (2023). The effect of a reduced dose of enzalutamide on fatigue and cognition.. Journal of Clinical Oncology. 41(16_suppl). 5051–5051. 1 indexed citations
11.
Engelhardt, Ellen G., Ronald P. Zweemer, Inge M. van Oort, et al.. (2022). The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care—A Systematic Review. Cancers. 14(4). 1059–1059. 45 indexed citations
12.
Mehra, Niven, Karim Fizazi, Johann S. de Bono, et al.. (2022). Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. The Oncologist. 27(10). e783–e795. 11 indexed citations
13.
Donders, Rogier, et al.. (2021). The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer. British Journal of Clinical Pharmacology. 88(3). 1170–1178. 7 indexed citations
14.
Smits, Minke, Inge M. van Oort, Winald R. Gerritsen, et al.. (2021). Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. British Journal of Cancer. 126(6). 907–916. 9 indexed citations
15.
Doelen, Maarten J. van der, Hans M. Westgeest, Carin A. Uyl‐de Groot, et al.. (2020). Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer. International Journal of Cancer. 148(2). 385–395. 26 indexed citations
16.
Surcel, C., Prasanna Sooriakumaran, Alberto Briganti, et al.. (2014). Preferences in the management of high‐risk prostate cancer among urologists in E urope: results of a web‐based survey. British Journal of Urology. 115(4). 571–579. 22 indexed citations
17.
Coenen, J.L., Peter van den Berg, Inge M. van Oort, et al.. (2013). A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients. European Journal of Cancer. 49. 4 indexed citations
18.
Fortuin, Ansje S., Willem M. L. L. G. Deserno, Hanneke Meijer, et al.. (2012). Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases. International Journal of Radiation Oncology*Biology*Physics. 84(3). 712–718. 46 indexed citations
19.
Hinnen, Karel A., Michael Schaapveld, Marco van Vulpen, et al.. (2011). Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis. Journal of Clinical Oncology. 29(34). 4510–4515. 66 indexed citations
20.
Hambrock, Thomas, Jurgen J. Fütterer, Henkjan Huisman, et al.. (2008). Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility. Investigative Radiology. 43(10). 686–694. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Steuber Breakdown of academic impact, for papers by Samson W. Fine Breakdown of academic impact, for papers by Scott Williams Breakdown of academic impact, for papers by Piet Ost Breakdown of academic impact, for papers by Thomas Wiegel Breakdown of academic impact, for papers by Daniel E. Spratt Breakdown of academic impact, for papers by Michael A. Gorin Breakdown of academic impact, for papers by Hans Heinzer Breakdown of academic impact, for papers by Soroush Rais‐Bahrami Breakdown of academic impact, for papers by Raymond Miralbell
Rankless by CCL
2026